title: Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes.
abstract: OBJECTIVE
  To compare 12-month outcomes and clinical presentations between first and second eyes of patients who developed neovascular age-related macular degeneration (nAMD) in both eyes and received ranibizumab intravitreal therapy (IVT).
  
  
  METHODS
  This is a retrospective case series of 45 patients undergoing IVT for unilateral nAMD who subsequently developed second-eye nAMD. At each visit, both eyes underwent visual acuity (VA) measurement and optical coherence tomography (OCT).
  
  
  RESULTS
  In second eyes, 53% were asymptomatic at baseline, with OCT retinal fluid as the only sign of nAMD among 33% of patients. In eyes with baseline VA >6/9, 82% of second treated eyes maintained this vision versus 12% of first eyes (p = 0.05). At 12 months, 70% of second eyes were fluid free versus 41% of first eyes (p = 0.02).
  
  
  CONCLUSIONS
  A large proportion of patients are asymptomatic at diagnosis of second-eye nAMD. Early intervention following earlier detection of nAMD in the second eye may lead to improved clinical outcomes.
authors.affiliation: Sydney Institute of Vision Science, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Jamie K
authors.initials: JK
authors.lastname: Chew
authors.forename: Meidong
authors.initials: M
authors.lastname: Zhu
authors.forename: Geoffrey K
authors.initials: GK
authors.lastname: Broadhead
authors.forename: Kehui
authors.initials: K
authors.lastname: Luo
authors.forename: Thomas
authors.initials: T
authors.lastname: Hong
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Chang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011379:Prognosis; D000069579:Ranibizumab / Q000008:administration & dosage*; D012160:Retina / Q000473:pathology*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
keywords: Anti-vascular endothelial growth factor; Choroidal neovascularization; Macular degeneration; Neovascular eye disease